Economic Evaluation of Screening Strategies for Thalassaemia Prevention: A Case Study From Thailand

Tenkorang, Phyllis; Wongnak, Phrutsamon; Kiatpakdee, Benjaporn; Paiboonsukwong, Kittiphong; Nasir, Na'ima; Atuire, Caesar; Painter, Chris; Pan-ngum, Wirichada

doi:10.34172/ijhpm.9851

Economic Evaluation of Screening Strategies for Thalassaemia Prevention: A Case Study From Thailand

Document Type : Original Article

Authors

Phyllis Tenkorang ¹

Phrutsamon Wongnak ²

Benjaporn Kiatpakdee ³

Kittiphong Paiboonsukwong ³

Na'ima Nasir ¹

Caesar Atuire ¹

Chris Painter ¹^{, 2}^{, 4}

Wirichada Pan-ngum ²^{, 5}

¹ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

² Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

³ Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand

⁴ Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao People’s Democratic Republic

⁵ Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

10.34172/ijhpm.9851

Abstract

Background
Thalassaemia is a genetic blood disorder endemic in Thailand. Management of severe thalassaemia utilises significant resources posing a substantial socio-economic burden; thus, prevention has been identified as a more sustainable approach to address thalassaemia. This study evaluated the cost-effectiveness and budget impact of various thalassaemia screening strategies in Thailand, including both pre-conception and post-conception approaches.

Methods
A cost-effectiveness analysis (CEA), from the Thai healthcare payer’s perspective, was conducted using decision analytic modelling. Decision trees were used to estimate the incremental screening cost per severe thalassaemia birth averted for four main screening strategies compared to “no screening”: post-conception screening (Strategy 1), pre-conception screening with targeted deoxyribonucleic acid (DNA) analysis (Strategy 2), pre-conception screening with universal DNA analysis (Strategy 3), and a combination of pre-conception and post-conception screening (Strategy 4). The cost-effectiveness threshold (CET) used was the lifetime cost of managing severe thalassaemia in Thailand. The annual budget impact of the upfront costs of implementing these strategies was also estimated.

Results
Strategies 1, 2, and 4 were cost-saving compared to the threshold of the average lifetime cost of managing severe thalassaemia in Thailand, $21,017. Strategy 4 had the lowest screening cost of $6773 [$4522–$10 066] per severe thalassaemia birth averted. Strategy 2 cost $8977 [$5689–$13 956] per severe thalassaemia birth averted, and Strategy 1 cost $10 474 [$7121–$15 734] per severe thalassaemia birth averted. In contrast, Strategy 3 cost $57 692 [$33 240–$96 123] per severe thalassaemia birth averted and is not cost-saving. The annual budget impact of the upfront costs of implementing thalassaemia screening ranged from $1.30 million to $288.93 million, depending on the strategy adopted and uptake rates.

Conclusion
Post-conception thalassaemia screening is cost-saving in Thailand. Combining pre-conception and postconception screening strategies may offer even better value for money in the Thai context, but with a higher upfront cost of implementation.

Keywords

Thalassaemia

Pre-conception Screening

Post-conception Screening

Cost-Effectiveness Analysis

Budget Impact Analysis

Thailand

1. Sarnaik SA. Thalassemia and related hemoglobinopathies. Indian J Pediatr. 2005;72(4):319–24. doi:10.1007/BF02724015

2. Hossain MS, Raheem E, Sultana TA, et al. Thalassemias in South Asia: clinical lessons learnt from Bangladesh. Orphanet J Rare Dis. 2017;12(1):93. doi:10.1186/s13023-017-0643-z

3. Tuo Y, Li Y, Li Y, et al. Global, regional, and national burden of thalassemia, 1990–2021: a systematic analysis for the global burden of disease study 2021. eClinicalMedicine. 2024;72:102619. doi:10.1016/j.eclinm.2024.102619

4. Tran DC, Dang AL, Hoang TNL, et al. Prevalence of thalassemia in the vietnamese population and building a clinical decision support system for prenatal screening for Thalassemia. Mediterr J Hematol Infect Dis. 2023;15(1):e2023026. doi:10.4084/MJHID.2023.026

5. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115(22):4331-4336. doi:10.1182/blood-2010-01-251348

6. Weatherall DJ. Fortnightly review: The thalassaemias. BMJ. 1997;314(7095):1675. doi:10.1136/bmj.314.7095.1675

7. Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018;391(10116):155-167. doi:10.1016/S0140-6736(17)31822-6

8. Economidou EC, Angastiniotis M, Avraam D, Soteriades ES, Eleftheriou A. Addressing Thalassaemia management from patients’ perspectives: an international collaborative assessment. Medicina. 2024;60(4):650. doi:10.3390/medicina60040650

9. Hokland P, Daar S, Khair W, et al. Thalassaemia—A global view. Br J Haematol. 2023;201(2):199-214. doi:10.1111/bjh.18671

10. Charoenkwan P, Komvilaisak P, Thepsuthummarat K, Seksarn P, Torcharus K. Causes of hospitalizations in pediatric patients with thalassemia under the National Health Coverage Scheme in Thailand. Thalass Rep. 2024;14(1):10-17. doi:10.3390/thalassrep14010002

11. Lorey F. Asian immigration and public health in California: thalassemia in newborns in California. J Pediatr Hematol Oncol. 2000;22(6):564-566. doi:10.1097/00043426-200011000-00024

12. Taher AT, Musallam KM, Cappellini MD. β-Thalassemias. N Engl J Med. 2021;384(8):727-743. doi:10.1056/NEJMra2021838

13. Bellis G, Parant A. Beta-thalassemia in Mediterranean countries. Findings and outlook. Investigaciones Geográficas. 2022;(77):129-138. doi:10.14198/INGEO.19079

14. Fucharoen S, Winichagoon P. Hemoglobinopathies in Southeast Asia: molecular biology and clinical medicine. Hemoglobin. 1997;21(4):299-319. doi:10.3109/03630269709000664

15. Leelahavarong P, Chaikledkaew U, Hongeng S, Kasemsup V, Lubell Y, Teerawattananon Y. A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand. BMC Health Serv Res. 2010;10(1):209. doi:10.1186/1472-6963-10-209

16. Yousuf R, Akter S, Wasek SM, et al. Thalassemia: a review of the challenges to the families and caregivers. Cureus. 2022;14(12):e32491. doi:10.7759/cureus.32491

17. Tarım HŞ, Öz F. Thalassemia major and associated psychosocial problems: a narrative review. Iran J Public Health. 2022;51(1):12-18. doi:10.18502/ijph.v51i1.8287

18. Massey K, Phommasone K, Lee V, et al. Systematic review of economic evaluations in thalassaemia screening programmes globally: developing guidance for low- and middle-income (LMIC) settings. BMJ Open. 2026;16:e108768. doi:10.1136/bmjopen-2025-108768

19. Wanapirak C, Pattanapongthorn J, Winichagoon P, Fucharoen S. Prevention and control of thalassemia in Thailand. In: Kumar D, ed. Genomics and Health in the Developing World. Oxford University Press; 2012. doi:10.1093/med/9780195374759.003.0063

20. Amarasinghe N, Amarasena A, Thabrew A, et al. Redesigning new policy options for thalassemia prevention in Sri Lanka. Thalass Rep. 2022;12(4):135-142. doi:10.3390/thalassrep12040018

21. Su Y, Xie J, He J, et al. Screening and treatment of thalassemia. Clinica Chimica Acta. 2025;570:120211. doi:10.1016/j.cca.2025.120211

22. Salama RAA, Saleh AK. Effectiveness of premarital screening program for thalassemia and sickle cell disorders in Ras Al Khaimah, United Arab Emirates. J Genet Med. 2016;13(1):26-30. doi:10.5734/jgm.2016.13.1.26

23. State of Thailand Population report 2015-Thai Family. https://thailand.unfpa.org/sites/default/files/pub-pdf/State%20of%20Thailand%20Population%20report%202015-Thai%20Family_en.pdf. Accessed July 26, 2025.

24. Tan HY, Hussein N, Lee YK, Abdul Malik TF. Adolescents’ experiences and views of the national school-based thalassaemia screening programme in Malaysia: a qualitative study. J Community Genet. 2023;14(4):361-369. doi:10.1007/s12687-023-00656-w

25. Research Report: An evaluation of thalassemia prevention and control in pregnancy program. HITAP website. https://www.hitap.net/en/document/thalassemia-screening-pregnant-women/. Accessed May 26, 2025.

26. NSO. Population and Housing Census. https://www.nso.go.th/nsoweb/main/summano/aE?set_lang=en. Accessed May 26, 2025.

27. Paiboonsukwong K, Jopang Y, Winichagoon P, Fucharoen S. Thalassemia in Thailand. Hemoglobin. 2022;46(1):53-57. doi:10.1080/03630269.2022.2025824

28. Clinical Practice Guidelines Thalassemia 2014 content. http://thalassemia.or.th/thal-book/CPG_Thalassemia_2014-content.pdf. Accessed May 27, 2025.

29. Riewpaiboon A, Nuchprayoon I, Torcharus K, Indaratna K, Thavorncharoensap M, Ubol B. Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children. BMC Res Notes. 2010;3(1):29. doi:10.1186/1756-0500-3-29

30. NHSO Thailand. https://www.asean-ssa.org/files/Organisation%20Profiles/NHSO%20Thailand.pdf. Accessed January 10, 2025.

31. Abortion (Sections 301-305) | Thailand Law Library. 2015. https://library.siam-legal.com/thai-law/criminal-code-abortion-sections-301-305/. Accessed February 23, 2025.

32. Sattaratanamai C, Saerawattanakul N, Narmraungsri P, et al. Cost-effectiveness of prevention and control for thalassemia in pregnant women at Surin Hospital. Thai J Hematol Transfus Med. 2006;16(1).

33. Charoenkwan P, Wanapirak C, Suntaranon A, Sanguansermsri T. Prenatal screening and control of severe thalassemia under the national universal health coverage in Chiang Mai. J Hematol Transfus Med. 2005;15(2):105-110.

34. Malasai K, Jittikoon J, Talungchit P, Youngkong S, Udomsinprasert W, Chaikledkaew U. Cost-effectiveness analysis of different prenatal screening strategies for the prevention of severe thalassemia in Thailand. Clinicoecon Outcomes Res. 2025;17:835-848. doi:10.2147/CEOR.S544493

35. Malasai K, Jittikoon J, Udomsinprasert W, et al. Cost-benefit analysis of genetic testing as a prenatal diagnostic tool for thalassemia: a single-center study from Central Thailand. Clinicoecon Outcomes Res. 2025;17:33-43. doi:10.2147/CEOR.S500802

36. Nuinoon M, Rattanaporn P, Benjchareonwong T, et al. Genetic predictions of life expectancy in southern Thai patients with β0-thalassemia/Hb E. Biomed Rep. 2022;16(6):52. doi:10.3892/br.2022.1535

37. Yadee J, Permsuwan U, Guntawongwan K, Himakalasa W, Buddhawongsa P. Discounting money and health effects from communicable and noncommunicable diseases in Thailand. Sci Rep. 2023;13(1):3324. doi:10.1038/s41598-023-30559-2

38. National Health Security Office. Announcement of the National Health Security Office Re: Payment of Public Health Service Expenses for Health Promotion and Disease Prevention Services (Basic Services) B.E. 2568. 2025. https://www.nhso.go.th/th/docman-document/nhso-payment-condition/nhso-payment-service-fees-for-health-support-disease-prevention/2568-3/54822-3-ppfs/file.

39. Thai Baht to US Dollars Exchange Rate. https://www.xe.com/currencyconverter/convert/?Amount=1&From=THB&To=USD. Accessed July 30, 2025.

40. Sukphanitnan S. Diagnosis of Thalassaemia carriers. http://www.thalassemia.or.th/thaiversion/diag-carrier-th.htm. Accessed July 3, 2025.

41. Wanapirak C, Muninthorn W, Sanguansermsri T, Dhananjayanonda P, Tongsong T. Prevalence of thalassemia in pregnant women at Maharaj Nakorn Chiang Mai Hospital. J Med Assoc Thai. 2004;87(12):1415-1418.

42. Wong P, Thanormrat P, Srithipayawan S, et al. Risk of a couple having a child with severe thalassaemia syndrome, prevalence in lower Northern Thailand. Southeast Asian J Trop Med Public Health. 2006;37(2):366-369.

43. Mendelian Inheritance - an overview | ScienceDirect Topics. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/mendelian-inheritance. Accessed July 3, 2025.

44. Punnett Square - an overview | ScienceDirect Topics. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/punnett-square. Accessed July 3, 2025.

45. Population statistics by civil registration. https://stat.bora.dopa.go.th/stat/statnew/statMONTH/statmonth/#/mainpage. Accessed July 3, 2025.

46. World Bank. GDP deflator (base year varies by country). World Bank Open Data; 2024. https://data.worldbank.org/indicator/NY.GDP.DEFL.ZS.

47. Weatherall DJ. Keynote address: The challenge of thalassemia for the developing countries. Ann N Y Acad Sci. 2005;1054:11-17. doi:10.1196/annals.1345.002

48. Benefit-Cost Ratio (BCR): Definition, Formula, and Example. Investopedia website. https://www.investopedia.com/terms/b/bcr.asp. Accessed July 30, 2025.

49. Briggs AH, Claxton K, Sculpher MJ. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2011.

50. Briggs AH, Ades AE, Price MJ. Probabilistic sensitivity analysis for decision trees with multiple branches: use of the dirichlet distribution in a Bayesian framework. Medical Decision Making. 2003;23(4):341-350. doi:10.1177/0272989X03255922

51. Sims A, Fairbairn K, Cognigni P. ‘rdecision’ Package for Decision Analytic Modelling in Health Economics. https://cran.r-project.org/web/packages/rdecision/refman/rdecision.html. Accessed September 16, 2025.

52. Abel L, Quaife M. A pregnant pause: rethinking economic evaluation in contraception and pregnancy. Value Health. 2022;25(1):32-35. doi:10.1016/j.jval.2021.07.009

53. Rahim ASA, Nour El Huda AR, Safurah J. A systematic review on thalassaemia screening and birth reduction initiatives: cost to success. Med J Malaysia. 2024;79(3):348-359.

54. Ahmadnezhad E, Sepehrvand N, Jahani FF, et al. Evaluation and cost analysis of national health policy of thalassaemia screening in West-Azerbaijan province of Iran. Int J Prev Med. 2012;3(10):687-692.

55. Esmaeilzadeh F, Ahmadi B, Vahedi S, Barzegari S, Rajabi A. Major thalassemia, screening or treatment: an economic evaluation study in Iran. Int J Health Policy Manag. 2022;11(7):1112-1119. doi:10.34172/ijhpm.2021.04

56. Leung KY, Lee CP, Tang MHY, et al. Cost-effectiveness of prenatal screening for thalassaemia in Hong Kong. Prenat Diagn. 2004;24(11):899-907. doi:10.1002/pd.1035

57. Ginsberg GM, Tulchinsky T, Goldfarb A, Filon D. Cost-benefit analysis of a national thalassemia prevention programme in Israel. Journal of Medical Screening. 1998;5(3):120-126. doi:10.1136/jms.5.3.120

58. Ostrowsky JT, Lippman A, Scriver CR. Cost-benefit analysis of a thalassemia disease prevention program. Am J Public Health. 1985;75(7):732-736. doi:10.2105/ajph.75.7.732

59. Gregg AR, Aarabi M, Klugman S, et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(10):1793. doi:10.1038/s41436-021-01203-z

60. Ghiossi CE, Goldberg JD, Haque IS, Lazarin GA, Wong KK. Clinical utility of expanded carrier screening: reproductive behaviors of at-risk couples. J Genet Counsel. 2018;27(3):616-625. doi:10.1007/s10897-017-0160-1

61. Biswas S, Mollah S, Tiwari PK. Optimal control analysis of thalassemia: modeling the impact of awareness. Eur Phys J Plus. 2024;139(2):128. doi:10.1140/epjp/s13360-024-04926-5

62. Kim S, Tridane A. Thalassemia in the United Arab Emirates: Why it can be prevented but not eradicated. PLoS One. 2017;12(1):e0170485. doi:10.1371/journal.pone.0170485

63. Kanokwan S, Jaruwan T, Pattara S, Goonnapa F, Supan F. Assessment of thalassemia screening program at peripheral health care facilities. J Med Tech Phy Ther. 2013;25(2).

64. Yamsri S, Sanchaisuriya K, Fucharoen G, Sae-ung N, Ratanasiri T, Fucharoen S. Prevention of severe thalassemia in northeast Thailand: 16 years of experience at a single university center. Prenat Diagn. 2010;30(6):540-546. doi:10.1002/pd.2514

65. Tongsong T, Wanapirak C, Sirivatanapa P, et al. Prenatal control of severe thalassaemia: Chiang Mai Strategy. Prenat Diagn. 2000;20(3):229-234. doi:10.1002/(SICI)1097-0223(200003)20:3<229::AID-PD790>3.0.CO;2-3

66. Frazer E. Thailand: A Family Planning Success Story. Context Institute; 2011. https://www.context.org/iclib/ic31/frazer/. Accessed July 14, 2025.

67. Ramanarayanan D. Planning, Pleasure, and Progress: How ICFP 2022 Advanced the Family Planning Dialogue. New Security Beat website. 2023. https://www.newsecuritybeat.org/2023/02/planning-pleasure-progress-icfp-2022-advanced-family-panning-dialogue/. Accessed July 14, 2025.

68. Thailand TH: Contraceptive Prevalence: Any Methods: % of Women Aged 15-49 | Economic Indicators. CEIC website. https://www.ceicdata.com/en/thailand/health-statistics/th-contraceptive-prevalence-any-methods--of-women-aged-1549. Accessed July 14, 2025.

69. Goonasekera HW, Paththinige CS, Dissanayake VHW. Population screening for hemoglobinopathies. Annu Rev Genomics Hum Genet. 2018;19(1):355-380. doi:10.1146/annurev-genom-091416-035451

70. Xu JZ, Tanongsaksakul W, Suksangpleng T, et al. Knowledge, cultural, and structural barriers to thalassemia screening in migrant populations in Thailand. Blood. 2018;132:2228. doi:10.1182/blood-2018-99-114117

71. Buakhao J, Khumpun P, Winichagoon P, Fucharoen S, Paiboonsukwong K. Prevalence and characterization of thalassemia among migrant workers from Cambodia, Lao PDR and Myanmar in Thailand. Southeast Asian J Trop Med Public Health. 2017;48(4):864-874.

72. Economic Community - ASEAN Main Portal. https://asean.org/our-communities/economic-community/. Accessed June 5, 2025.

73. Xu JZ, Foe M, Tanongsaksakul W, et al. Identification of optimal thalassemia screening strategies for migrant populations in Thailand using a qualitative approach. BMC Public Health. 2021;21(1):1796. doi:10.1186/s12889-021-11831-4

74. McMichael C, Healy J. Health equity and migrants in the Greater Mekong Subregion. Glob Health Action. 2017;10(1):1271594. doi:10.1080/16549716.2017.1271594

75. Van Staveren I. Beyond utilitarianism and deontology: ethics in economics. Review of Political Economy. 2007 Jan 1;19(1):21-35. doi:10.1080/09538250601080776

76. Bozkurt G. Results from the North Cyprus Thalassemia Prevention Program. Hemoglobin. 2007;31(2):257-264. doi:10.1080/03630260701297204

77. Hasanshahi F, Khanjani N. Investigating the reasons for marriage among couples with thalassemia minor, in Iran. J Community Genet. 2021;12(4):507-513. doi:10.1007/s12687-021-00540-5

78. Suresh H, Jamil S, Padhi BK, Hossain MdJ. Thalassemia prevention: religious and cultural barriers to premarital screening in Bangladesh. Health Sci Rep. 2023;6(4):e1176. doi:10.1002/hsr2.1176

79. Boardman FK, Clark C, Jungkurth E, Young PJ. Social and cultural influences on genetic screening programme acceptability: a mixed‐methods study of the views of adults, carriers, and family members living with thalassemia in the UK. J Genet Couns. 2020;29(6):1026-1040. doi:10.1002/jgc4.1231

80. National Perinatal Registry Portal, Thailand. http://nprp.nhso.go.th/nprp/faces/login/login.jsf. Accessed July 11, 2025.